Ngalaba Mba Nile

Na Jenụwarị 22, 2025, "Ọgwụ Okike" bipụtara nsonaazụ nke Akeso mepụtara ọgwụ mgbochi PD-1/CTLA-4 nke nwere ọgwụ mgbochi abụọ nke PD-1/CTLA-4 n'onwe ya yana oxaliplatin na capecitabine maka ọgwụgwọ mbụ nke ọrịa afọ ma ọ bụ eriri afọ nke na-adịghị ahụkebe nke a na-apụghị ịgbanahụ n'ógbè ma ọ bụ nke na-agbasa ngwa ngwa...GỤKWUO»

Na Jenụwarị 8, 2025, Ụlọ Ọrụ Nlekọta Ngwaahịa Ọgwụ nke Mba China (NMPA) akwadola PADCEVTM (enfortumab vedotin) yana KEYTRUDA (pembrolizumab) maka ndị ọrịa toro eto nwere ọrịa kansa urothelial dị elu ma ọ bụ nke metastatic (la/mUC). Nkwado NMPA maka enfortumab vedotin na mbo...GỤKWUO»

Na Febụwarị 17, 2025, Innovent Biologics kwupụtara na protein PD-1/IL-2α-bias nke mbụ n'ime ọkwa ya, IBI363, enwetala Nhọpụta Fast Track nke abụọ (FTD) site na US Food and Drug Administration (FDA). Nkọwa a metụtara ọgwụgwọ nke enweghị ike iwepụ ihe ndị a na-apụghị iwepụ, ...GỤKWUO»

Na Jenụwarị 16, 2025, IMPACT kwupụtara na Senaparib Capsules (派舒宁®) enwetala ikike ahịa na China site na National Medical Products Administration (NMPA) dị ka monotherapy maka ọgwụgwọ mmezi nke ndị okenye nwere epithelial dị elu (FIGO Stages III na IV)...GỤKWUO»

Na Febụwarị 7, 2025, Sichuan Kelun-Biotech Biopharmaceutical kwupụtara nkwenye nke Cetuximab N01 Injection site na National Medical Products Administration maka ọgwụgwọ nke kansa afọ ime metastatic (mCRC) na China. Nkwado a dabere na nnukwu ọmụmụ ihe ahụike nke ọkwa nke atọ nke ụlọ ọgwụ...GỤKWUO»

Na Febụwarị 10, 2025, CARsgen Therapeutics kwupụtara na onye mbụ ejiri ọgwụgwọ allogeneic BCMA CAR-T nke e mepụtara na ikpo okwu THANK-u Plus™ gwọọ ya enwetala nzaghachi zuru oke (sCR) na obere ihe na-adịghị mma nke ọrịa fọdụrụ (MRD) na nyocha ụbọchị-28. Emepụtara n'ime ụlọ ọgwụ...GỤKWUO»

Na Jenụwarị 29, 2025, otu ndị nyocha China bipụtara otu isiokwu akpọrọ "Neoadjuvant pyrotinib na trastuzumab na ọrịa kansa ara HER2 dị mma na-enweghị nzaghachi mbụ (NeoPaTHer): irè, nchekwa, na nyocha biomarker nke ọmụmụ ihe a na-atụ anya ya, nke nwere ọtụtụ etiti, nke emere maka nzaghachi" na th...GỤKWUO»

Na Jenụwarị 26, 2025, Center for Drug Evaluation (CDE) nke China National Medical Products Administration kwupụtara na a chọrọ ka a tinye ọgwụ LM-108 n'ọgwụgwọ breakthrough maka etuto siri ike dị elu nwere enweghị ike microsatellite (MSI-H) ma ọ bụ ntụpọ ndozi adịghị mma (dMMR) na...GỤKWUO»

Na Jenụwarị 20, National Medical Products Administration (NMPA) kwadoro ọgwụgwọ njikọta nke cisplatin na gemcitabine nke e ji aka mee nke na-akpata ọrịa kansa nasopharyngeal (NPC) ugboro ugboro ma ọ bụ nke na-akpata ọrịa kansa nasopharyngeal (NPC) nke ọhụrụ. ...GỤKWUO»

Na Jenụwarị 16, 2025, Ụlọ Ọrụ Nlekọta Ngwaahịa Ahụike Mba nke China (NMPA) akwadola ojiji ọgwụ ọhụrụ (NDA) nke limertinib maka ọgwụgwọ ndị okenye nwere ọrịa kansa akpa ume EGFR T790M nke a na-akpọ "non-small cell lung cancer" (NSCLC) ma ọ bụ nke a na-akpọ "metastatic measurement EGFR T790M". Banyere Limertinib Limertinib ...GỤKWUO»

Na Jenụwarị nke asatọ, Center for Drug Evaluation (CDE) nke National Medical Products Administration (NMPA) enyela Breakthrough Therapy Nomination (BTD) maka IBI343, TOPO1i anti-CLDN18.2 ADC nke nwere ike ịbụ nke kacha mma na ọkwa, dị ka otu ọgwụgwọ maka ọgwụgwọ nke CLDN18.2-positive advanced pancr...GỤKWUO»

Na Jenụwarị 8, 2025, Center for Drug Evaluation (CDE) nke National Medical Products Administration (NMPA) na China nyere 9MW2821 Breakthrough Therapy Nomination (BTD). E nyere 9MW2821 yana toripalimab, antibody anti-PD-1 monoclonal, maka ọgwụgwọ-enweghị isi, enweghị ntụsara ahụ...GỤKWUO»